Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 15, 2009

VistaGen and Capsant to Develop Stem Cell Technology for Drug R&D

  • VistaGen and Capsant are working together to develop and commercialize a new generation of human stem cell-based biological tools. The companies will combine their cell biology and 3-D cell culture platforms.

    VistaGen is focused on commercializing the power of stem cell technologies to transform the ways new drugs are discovered and tested. Capsant’s OrganDot 3D™ technology is a high-throughput, in vitro drug testing platform that uses stem cell-based, 3-D micro-organ tissue cultures.

    “Capsant’s OrganDot 3D technology significantly expands our ability to deliver a valuable synergistic combination of leading stem cell biology, 3-D tissue culture and electrophysiological technologies, and a multidimensional automated knowledge base through our Clinical Trials in a Test Tube™ platform,” remarks Ralph Snodgrass, Ph.D., VistaGen CEO.

    “After a comprehensive global evaluation of stem cell technologies,” says Riccardo Pigliucci, Capsant executive chairman, “our scientific team easily concluded that VistaGen’s stem cell differentiation technologies are the best at producing functional human cells reproducibly and at the scale needed to optimize the commercial potential of our advanced 3-D micro-organ culture systems.”

    ---

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »